Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

FDA Blocks PRC2 Drug Path; Fulcrum Cuts 85% Workforce After Collapse

A major restructuring has hit Fulcrum Therapeutics after the company halted development of its lead sickle cell therapy following FDA-linked safety concerns. The biotech will reduce its workforce by around 85%, leaving only nine employees, as regulatory risk tied to
  • News
FDA Blocks PRC2 Drug Path; Fulcrum Cuts 85% Workforce After Collapse

Billions Chase Lung Cancer; Yet Liver Cancer Steals the Spotlight

Pharmaceutical companies continue to pour billions into PD-1/VEGF bispecific antibodies after strong lung cancer results fueled industry enthusiasm. However, analysts increasingly question whether the sector is targeting the most valuable opportunity. As global Phase 3 programs expand, emerging evidence suggests
  • News
Billions Chase Lung Cancer; Yet Liver Cancer Steals the Spotlight

China Becomes Pharma Powerhouse; RA Capital Swiftbridge Triggers Global Shift

RA Capital has launched Swiftbridge, a new initiative designed to give its biotech portfolio companies structured access to China’s clinical trial ecosystem. Introduced in mid-2025, the program removes a key bottleneck in global drug development by simplifying entry into China’s
  • News
China Becomes Pharma Powerhouse; RA Capital Swiftbridge Triggers Global Shift

Takeda Pay-for-Delay Shock; $2.5B Verdict Wipes Profit Into Loss

A U.S. federal jury in Boston has ruled against Takeda in a pay-for-delay antitrust case involving its constipation drug Amitiza, forcing the company to book a $2.5 billion legal provision and swing to a FY2025 net loss. The decision marks
  • News
Takeda Pay-for-Delay Shock; $2.5B Verdict Wipes Profit Into Loss

U.S. and China AI Drug Race Is Breaking Regulatory Control; FDA Pressure and Data Failures Are Escalating Fast

At BioSpace’s NextGen 2026 discussion, leading biotech executives from the United States and China highlighted a growing strategic divide in pharmaceutical innovation. The conversation revealed how artificial intelligence is now accelerating drug discovery and clinical decision-making, while simultaneously exposing weaknesses
  • News
U.S. and China AI Drug Race Is Breaking Regulatory Control; FDA Pressure and Data Failures Are Escalating Fast

AI Is Accelerating Drug Development; But Data Risks Could Break It

BioSpace’s NextGen 2026 biotech leaders highlighted at a recent industry discussion how artificial intelligence is rapidly reshaping drug development while exposing a critical weakness in pharmaceutical innovation: data quality. Executives from emerging biotech companies emphasized that while AI accelerates discovery
  • News
AI Is Accelerating Drug Development; But Data Risks Could Break It

Aragen completes FDA Fast Track mAb scale-up; what enabled this 9-month turnaround

Aragen has completed technology transfer and initiated first commercial-scale GMP manufacturing runs for Renaissance Pharma’s lead monoclonal antibody Daretabart at its Bengaluru facility in India. The company originally developed the cell line and early process at its Morgan Hill site
  • News
Aragen completes FDA Fast Track mAb scale-up; what enabled this 9-month turnaround

Why Inspection Readiness Is Becoming Harder; Digital GMP Raises New Risks

In a recent interview with Christopher Cole of Pharmaceutical Technology, Henrik Johanning from Epista Life Science discussed how pharmaceutical manufacturing and regulatory systems in Europe are shifting from 2025 into 2026. He explained that quality risk management, digital GMP, and
  • News
Why Inspection Readiness Is Becoming Harder; Digital GMP Raises New Risks

FDA Leadership Shakeup Raises Alarm; DTC Drug Ads Face Sudden Enforcement Shift

In September 2025, President Donald Trump called for stricter enforcement of existing rules on direct-to-consumer (DTC) prescription drug advertising by the U.S. Food and Drug Administration (FDA). Around the same period, HHS Secretary Robert F. Kennedy Jr. also criticized pharmaceutical
  • News
FDA Leadership Shakeup Raises Alarm; DTC Drug Ads Face Sudden Enforcement Shift

AI in Clinical Trials Faces Trust Crisis; Regulatory Uncertainty Grows

A recent survey by the Pistoia Alliance at the Clinical Trials Technology Congress (CTTC) in London shows that trust issues and regulatory uncertainty continue to slow artificial intelligence adoption in clinical trials. Although AI already delivers early value in clinical
  • News
AI in Clinical Trials Faces Trust Crisis; Regulatory Uncertainty Grows